芦可替尼联合聚乙二醇干扰素α-2a治疗新诊断真性红细胞增多症患者
COMBI II 2期试验报告2年研究结束结果,评估芦可替尼联合低剂量聚乙二醇干扰素α-2a治疗25例新诊断真性红细胞增多症患者的安全性和疗效。主要终点为安全性,关键次要终点包括血液学参数、生活质量和JAK2V617F等位基因频率。24个月时外周血细胞计数缓解率92%,按2013年ELN和IWG-MPN缓解标准14例(56%)达缓解,中位JAK2V617F等位基因频率从47%降至7%。
要点
- 24个月外周血细胞计数缓解率92%,按2013 ELN/IWG-MPN标准56%达缓解(完全缓解12%,部分缓解44%)。
- 中位JAK2V617F等位基因频率从47%(95%CI 35-59)降至7%(95%CI 3-15),60%患者达分子学缓解。
- 腹部不适、盗汗、瘙痒和骨痛等MPN-SAF TSS条目显著改善,毒性可接受。
核心结论
- 联合治疗改善了血细胞计数、骨髓细胞度和纤维化,并降低了JAK2V617F等位基因频率,毒性可接受。
研究设计与样本
- 2期COMBI II临床试验,评估芦可替尼联合低剂量聚乙二醇干扰素α-2a治疗新诊断真性红细胞增多症患者。
- 纳入25例患者,中位年龄70岁,其中5例有既往血栓栓塞事件,3例经计算机断层扫描证实脾肿大。
主要发现
- 24个月时外周血细胞计数缓解率为92%。
- 按2013年欧洲白血病网和国际工作组-骨髓增殖性肿瘤研究缓解标准,24个月时14例(56%)达缓解,其中3例(12%)完全缓解,11例(44%)部分缓解。
- 骨髓增殖性肿瘤症状总症状评分中腹部不适、盗汗、瘙痒和骨痛显著减轻。
- 中位JAK2V617F等位基因频率从47%(95%CI 35-59)降至7%(95%CI 3-15),60%患者达分子学缓解。
- 2例停用两种研究药物,其中1例因进展为真性红细胞增多症后骨髓纤维化,该例也是唯一发生3级感染者;未观察到带状疱疹感染;无患者因精神症状停药。
关键数值与推荐
- 采用2013年欧洲白血病网和国际工作组-骨髓增殖性肿瘤研究缓解标准,包括症状、脾肿大、外周血计数和骨髓缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report the 2-year end-of-study results from the phase 2 COMBI II clinical trial investigating the combination treatment of ruxolitinib and low-dose pegylated interferon alfa-2a in patients with newly diagnosed polycythemia vera (PV). The primary outcome was safety and key secondary endpoints were efficacy, based on hematologic parameters, quality-of-life measurements, and JAK2V617F variant allele frequency (VAF). We used the 2013 European LeukemiaNet and International Working Group-Myeloproliferative Neoplasms Research remission criteria. The remission criteria included remissions in symptoms, splenomegaly, peripheral blood counts, and bone marrow. We included 25 patients with PV with a median age of 70 years; 5 of those had prior thromboembolic events and 3 had computed tomography-verified splenomegaly. Two patients stopped both study drugs; 1 of these due to progression to post-PV myelofibrosis, the only one with a grade 3 infection. No events of herpes zoster infections were observed. None of the patients discontinued treatment due to psychiatric symptoms. The peripheral blood cell count remission rate was 92% at 24 months. Using the 2013 European LeukemiaNet and International Working Group-Myeloproliferative Neoplasms Research remission criteria, 14 (56%) achieved remission at 24 months; 3 (12%) achieved complete remission and 11 (44%) achieved partial remission. The following items from the Myeloproliferative Neoplasm Symptom Total Symptom Score were significantly reduced: abdominal discomfort, night sweats, itching, and bone pain. The median JAK2V617F VAF decreased from 47% (95% confidence interval [CI], 35-59) to 7% (95% CI, 3-15), and 60% of patients achieved molecular remission. In conclusion, combination treatment improved cell counts; bone marrow cellularity, and fibrosis; and decreased JAK2V617F VAF; with acceptable toxicity in patients with PV. The trial was registered at www.clinicaltrialsregister.eu as #EudraCT2018-004150-13.
引用
- Sørensen AL, Skov V, Kjær L, et al. Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera. Blood Adv. 2024. PMID: 39163611. doi:10.1182/bloodadvances.2024013170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。